Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Janssen's Drug Pricing Report Emphasizes Value Of Rebates

Executive Summary

As political pressure on pricing continues to build, Janssen's first-ever transparency report notes average list price increase was 8.5% in 2016; annual pricing parties are no longer 'raves,' Raymond James & Associates says.


Related Content

Which Pharma Firm Increases US Prices The Most?
US Insulin Pricing Probe Clouds Prospects for Novo Nordisk, Others
Insulin Pricing, PBM Relationships Under Government Microscope
Where Will It End? Lilly’s US Price Concessions Increase 30% In 2016
J&J Outlines Pricing Transparency Plan, Will Others Follow?
Drug Pricing: PhRMA Report Aims To Shift Focus To Supply Chain


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst